Nukkleus Stock Today
| NUKK Stock | USD 1.80 0.09 5.26% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Nukkleus is selling for 1.80 as of the 22nd of November 2024. This is a 5.26 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.68. Nukkleus has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Nukkleus symbol was changed from BRLI on 26th of December 2023. Equity ratings for Nukkleus are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Software & Services | IPO Date 26th of December 2023 | Category Technology | Classification Information Technology |
Nukkleus Inc., a financial technology company, focuses on providing software and technology solutions for retail foreign exchange trading industry worldwide. Nukkleus Inc. operates as a subsidiary of Global Elite Holdings Ltd. Nukkleus operates under SoftwareApplication classification in the United States and is traded on OTC Exchange. The company has 2.53 M outstanding shares of which 67.52 K shares are now shorted by private and institutional investors with about 0.13 trading days to cover. More on Nukkleus
Moving against Nukkleus Stock
Nukkleus Stock Highlights
| Older Symbol | BRLI | |||||||||||||||||||||||||
| CEO | Emil Assentato | |||||||||||||||||||||||||
| Business Concentration | Application Software, Software - Application, Information Technology, NASDAQ Composite, Information Technology, Software, Software—Application, Technology (View all Sectors) | |||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||
Debt LevelsNukkleus can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nukkleus' financial leverage. It provides some insight into what part of Nukkleus' total assets is financed by creditors.
| ||||||||||||||||||||||||||
Nukkleus (NUKK) is traded on NASDAQ Exchange in USA. It is located in 525 Washington Boulevard, Jersey City, NJ, United States, 07310 and employs 12 people. Nukkleus was previously known as Brilliant Acquisition Corp and was traded on NASDAQ Exchange under the symbol BRLI. Nukkleus is listed under Application Software category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.33 M. Nukkleus conducts business under Software sector and is part of Information Technology industry. The entity has 2.53 M outstanding shares of which 67.52 K shares are now shorted by private and institutional investors with about 0.13 trading days to cover.
Nukkleus currently holds about 23.14 K in cash with 1.62 M of positive cash flow from operations.
Check Nukkleus Probability Of Bankruptcy
Ownership AllocationNukkleus holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Nukkleus Ownership Details
Nukkleus Historical Income Statement
Nukkleus Stock Against Markets
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.36) | Revenue Per Share 7.024 | Quarterly Revenue Growth (0.97) | Return On Assets (1.15) | Return On Equity (7.42) |
The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.